{"transactions":[{"id":756113,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-02T20:30:15.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":42671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":42671,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":42671},"source":{"system":"sec-edgar","filing":"0001777421-26-000005","document":"form4-06022026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000177742126000005/form4-06022026_040610.xml","form_type":"4"}},{"id":756112,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T20:30:15.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":21335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":127178,"source":{"system":"sec-edgar","filing":"0001777421-26-000005","document":"form4-06022026_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000177742126000005/form4-06022026_040610.xml","form_type":"4"}},{"id":796909,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-30T20:01:55.000Z","date":"2026-04-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":50000,"derivative":{"exercise_price":5.81,"expiration_date":"2036-04-27","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001777421-26-000003","document":"form4-04302026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000177742126000003/form4-04302026_080451.xml","form_type":"4"}},{"id":1123805,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-04T20:15:11.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":113246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":113246,"derivative":{"exercise_price":2.785,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":113246},"source":{"system":"sec-edgar","filing":"0001415889-25-015571","document":"form4-06042025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015571/form4-06042025_040601.xml","form_type":"4"}},{"id":1123804,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:15:11.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":56623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":105843,"source":{"system":"sec-edgar","filing":"0001415889-25-015571","document":"form4-06042025_040601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925015571/form4-06042025_040601.xml","form_type":"4"}},{"id":1308170,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:16:22.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":8966,"price":12.18,"value":109205.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":77388,"source":{"system":"sec-edgar","filing":"0000950170-25-003002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025003002/ownership.xml","form_type":"4"}},{"id":1315007,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":0,"derivative":{"exercise_date":"2025-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000950170-25-001232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025001232/ownership.xml","form_type":"4"}},{"id":1315006,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively."}],"balance_after":86354,"source":{"system":"sec-edgar","filing":"0000950170-25-001232","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017025001232/ownership.xml","form_type":"4"}},{"id":1497237,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T20:15:09.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":98440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":98440,"derivative":{"exercise_price":3.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":98440},"source":{"system":"sec-edgar","filing":"0001415889-24-015038","document":"form4-05312024_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015038/form4-05312024_040501.xml","form_type":"4"}},{"id":1497236,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T20:15:09.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":49220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":49220,"source":{"system":"sec-edgar","filing":"0001415889-24-015038","document":"form4-05312024_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924015038/form4-05312024_040501.xml","form_type":"4"}},{"id":1596825,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-05T21:10:23.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":54794,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":54794,"derivative":{"exercise_price":32.66,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":54794},"source":{"system":"sec-edgar","filing":"0000950170-24-025907","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024025907/ownership.xml","form_type":"4"}},{"id":1596824,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:10:23.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":37966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":81893,"source":{"system":"sec-edgar","filing":"0000950170-24-025907","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024025907/ownership.xml","form_type":"4"}},{"id":1681679,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:15:19.000Z","date":"2024-01-08","kind":"sale","planned":true,"acquired":false,"shares":667,"price":29.38,"value":19596.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price."}],"balance_after":43927,"source":{"system":"sec-edgar","filing":"0000950170-24-003632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024003632/ownership.xml","form_type":"4"}},{"id":1681678,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:15:19.000Z","date":"2024-01-08","kind":"sale","planned":true,"acquired":false,"shares":1608,"price":28.66,"value":46085.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price."}],"balance_after":44594,"source":{"system":"sec-edgar","filing":"0000950170-24-003632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024003632/ownership.xml","form_type":"4"}},{"id":1685574,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-05T21:50:26.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":5532,"price":29.46,"value":162972.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":46202,"source":{"system":"sec-edgar","filing":"0000950170-24-002514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024002514/ownership.xml","form_type":"4"}},{"id":1692846,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T22:35:50.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":3500,"derivative":{"exercise_date":"2024-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000950170-24-001210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024001210/ownership.xml","form_type":"4"}},{"id":1692845,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T22:35:50.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively."}],"balance_after":51734,"source":{"system":"sec-edgar","filing":"0000950170-24-001210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000095017024001210/ownership.xml","form_type":"4"}},{"id":1844707,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:50:51.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date."}],"balance_after":36200,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":36200},"source":{"system":"sec-edgar","filing":"0001209191-23-039733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123039733/doc4.xml","form_type":"4"}},{"id":1974085,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T22:14:23.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":42302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":42302,"derivative":{"exercise_price":40.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":42302},"source":{"system":"sec-edgar","filing":"0001209191-23-015742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123015742/doc4.xml","form_type":"4"}},{"id":1974084,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T22:14:23.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":29938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":47567,"source":{"system":"sec-edgar","filing":"0001209191-23-015742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123015742/doc4.xml","form_type":"4"}},{"id":2060529,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:39:56.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":689,"price":39.1,"value":26939.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price."}],"balance_after":17629,"source":{"system":"sec-edgar","filing":"0001209191-23-002433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123002433/doc4.xml","form_type":"4"}},{"id":2060528,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:39:56.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":1641,"price":38.22,"value":62719.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price."}],"balance_after":18318,"source":{"system":"sec-edgar","filing":"0001209191-23-002433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123002433/doc4.xml","form_type":"4"}},{"id":2060527,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:39:56.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":2508,"price":37.21,"value":93322.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023."}],"balance_after":19959,"source":{"system":"sec-edgar","filing":"0001209191-23-002433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123002433/doc4.xml","form_type":"4"}},{"id":2068180,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-01-05T01:38:29.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":7000,"derivative":{"exercise_date":"2023-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-23-001498","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123001498/doc4.xml","form_type":"4"}},{"id":2068179,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-05T01:38:29.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively."}],"balance_after":22467,"source":{"system":"sec-edgar","filing":"0001209191-23-001498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919123001498/doc4.xml","form_type":"4"}},{"id":2224677,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T20:41:38.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":2.81,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-038692","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122038692/doc4.xml","form_type":"4"}},{"id":2350531,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-05T01:58:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":20203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."}],"balance_after":20203,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":20203},"source":{"system":"sec-edgar","filing":"0001209191-22-016526","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122016526/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-03"}},{"id":2354964,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T01:03:53.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":13816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":13816,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":13816},"source":{"system":"sec-edgar","filing":"0001209191-22-015976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122015976/doc4.xml","form_type":"4"}},{"id":2354963,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-03-04T01:03:53.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":10500,"derivative":{"exercise_date":"2022-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-22-015976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122015976/doc4.xml","form_type":"4"}},{"id":2354962,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-04T01:03:53.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":13816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":18631,"source":{"system":"sec-edgar","filing":"0001209191-22-015976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122015976/doc4.xml","form_type":"4"}},{"id":2354961,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-04T01:03:53.000Z","date":"2022-01-01","kind":"sale","acquired":false,"shares":1148,"price":112.25,"value":128863.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022."}],"balance_after":4815,"source":{"system":"sec-edgar","filing":"0001209191-22-015976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122015976/doc4.xml","form_type":"4"}},{"id":2354960,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-04T01:03:53.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021."}],"balance_after":5963,"source":{"system":"sec-edgar","filing":"0001209191-22-015976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919122015976/doc4.xml","form_type":"4"}},{"id":2583740,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 84,375 shares as of August 30, 2021."}],"balance_after":80000,"derivative":{"exercise_price":14.25,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583739,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 30, 2021."}],"balance_after":82000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583738,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":207,"price":160.47,"value":33217.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.40 to $160.53, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":2391,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583737,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":2653,"price":159.64,"value":423524.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $160.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":2598,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583736,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":1515,"price":158.9,"value":240733.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.31 to $159.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":5251,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583735,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":3932,"price":157.77,"value":620351.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.305 to $158.245, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":6766,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583734,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":7425,"price":156.79,"value":1164165.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.22 to $157.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":10698,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583733,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":16115,"price":155.61,"value":2507655.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.22 to $156.19, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":18123,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583732,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":28669,"price":154.77,"value":4437101.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.22 to $155.215, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":34238,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583731,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":20645,"price":153.64,"value":3171897.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.16 to $154.15, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":62907,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583730,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":15839,"price":152.75,"value":2419407.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.16 to $153.155, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":83552,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583729,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":70000,"price":14.25,"value":997500.0,"ownership":{"direct":true},"balance_after":99391,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2583728,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-01T23:34:46.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":27000,"price":13.4,"value":361800.0,"ownership":{"direct":true},"balance_after":29391,"source":{"system":"sec-edgar","filing":"0001209191-21-054321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121054321/doc4.xml","form_type":"4"}},{"id":2611617,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"exercise","acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021."}],"balance_after":109000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611616,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":126,"price":141.63,"value":17845.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows:  760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021."}],"balance_after":2391,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611615,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":4054,"price":140.73,"value":570519.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":2517,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611614,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":2772,"price":139.85,"value":387664.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":6571,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611613,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":4419,"price":138.78,"value":613268.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":9343,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611612,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":6344,"price":137.72,"value":873695.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":13762,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611611,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":6814,"price":136.79,"value":932087.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":20106,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611610,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"sale","acquired":false,"shares":1471,"price":135.47,"value":199276.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price."}],"balance_after":26920,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2611609,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-06T22:19:30.000Z","date":"2021-08-04","kind":"exercise","acquired":true,"shares":26000,"price":13.4,"value":348400.0,"ownership":{"direct":true},"balance_after":28391,"source":{"system":"sec-edgar","filing":"0001209191-21-050228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121050228/doc4.xml","form_type":"4"}},{"id":2662322,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T21:01:12.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":25.04,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-21-042101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121042101/doc4.xml","form_type":"4"}},{"id":2806464,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T22:54:03.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 14,000 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 14,000 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 14,000 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 14,000 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-21-018327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121018327/doc4.xml","form_type":"4"}},{"id":2806463,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T22:54:03.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":84000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 84,000 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":84000,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":84000},"source":{"system":"sec-edgar","filing":"0001209191-21-018327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919121018327/doc4.xml","form_type":"4"}},{"id":2969007,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-24T21:42:53.000Z","date":"2020-11-23","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":31000,"derivative":{"exercise_price":21.77,"expiration_date":"2030-11-23","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001209191-20-060227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120060227/doc4.xml","form_type":"4"}},{"id":3227946,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T22:30:03.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":135000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0000899243-20-006978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000089924320006978/doc4.xml","form_type":"4"}},{"id":3502701,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":42619,"kind":"person","name":"Sepp-Lorenzino Laura","position":1,"cik":"0001777421","reported_name":"Sepp-Lorenzino Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-04T20:16:37.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 28, 2019 with respect to 150,000 shares of Common Stock, with 25% vesting on May 28, 2020 and the remainder vesting in thirty-six equal monthly installments thereafter."}],"balance_after":150000,"derivative":{"exercise_price":14.25,"expiration_date":"2029-05-27","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-034240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777421/000120919119034240/doc4.xml","form_type":"4"}}]}